Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Wiskott-Aldrich syndrome News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

This week

An EMA perspective on the regulatory approval of Waskyra®, the first gene therapy for the treatment of Wiskott-Aldrich Syndrome.

Earlier

Gene Therapy Cuts Severe Infections 93% In A Rare Immune Disease

From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott-Aldrich syndrome.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare Diseases - BioSpace

Recent research highlights large vessel vasculopathy as an underrecognized complication in Wiskott-Aldrich syndrome. This discovery may prompt further investigation into the cardiovascular risks associated with this rare genetic disorder.

FDA approves Waskyra (etuvetidigene autotemcel) as the first gene therapy for Wiskott-Aldrich syndrome. This landmark approval marks a significant advancement in the treatment options available for this rare immunodeficiency disorder.

Not rare diseases news,news about your rare disease.